company background image
GERN logo

Geron NasdaqGS:GERN Stock Report

Last Price

US$3.31

Market Cap

US$1.9b

7D

-3.8%

1Y

48.4%

Updated

27 Mar, 2024

Data

Company Financials +

GERN Stock Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

GERN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Geron Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Geron
Historical stock prices
Current Share PriceUS$3.31
52 Week HighUS$3.74
52 Week LowUS$1.64
Beta0.55
1 Month Change59.90%
3 Month Change53.95%
1 Year Change48.43%
3 Year Change109.49%
5 Year Change89.14%
Change since IPO-57.29%

Recent News & Updates

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Recent updates

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25
Is Geron (NASDAQ:GERN) A Risky Investment?

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

May 12
Is Geron (NASDAQ:GERN) Using Debt Sensibly?

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20
An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14
Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05
Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Geron: Waiting For Godot

Jul 15

Geron: TLR Is 10 Months Away

May 03

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Feb 25
Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron: Just One More Year Of Patience, Then Decision Time

Feb 23

With No Catalysts At ASH, Geron Corp. Remains In A Holding Pattern

Nov 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Nov 04
Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Geron: Still A Strong Buy After New Phase II Data And 20% Return

Oct 22

Geron: Potential For Mind-Bending Returns With Current Pipeline

Aug 19

Shareholder Returns

GERNUS BiotechsUS Market
7D-3.8%0.9%0.4%
1Y48.4%10.3%28.8%

Return vs Industry: GERN exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: GERN exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is GERN's price volatile compared to industry and market?
GERN volatility
GERN Average Weekly Movement28.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: GERN's share price has been volatile over the past 3 months.

Volatility Over Time: GERN's weekly volatility has increased from 16% to 29% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990141Chip Scarletthttps://www.geron.com

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation Fundamentals Summary

How do Geron's earnings and revenue compare to its market cap?
GERN fundamental statistics
Market capUS$1.95b
Earnings (TTM)-US$184.13m
Revenue (TTM)US$237.00k

8,213x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GERN income statement (TTM)
RevenueUS$237.00k
Cost of RevenueUS$123.74m
Gross Profit-US$123.50m
Other ExpensesUS$60.62m
Earnings-US$184.13m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.31
Gross Margin-52,110.97%
Net Profit Margin-77,690.72%
Debt/Equity Ratio33.0%

How did GERN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.